CAR-T cell therapy
![IVS-3001 Gets Fast Track Status for RCC Treatment](https://pharmtales.com/wp-content/uploads/2023/08/IVS-3001-been-given-Fast-Track-Designation-by-the-FDA-for-RCC.jpg)
IVS-3001 been given Fast Track Designation by the FDA for RCC
SG Tylor
The FDA has granted fast track designation (FTD) to IVS-3001, an innovative chimeric antigen receptor (CAR) T-cell therapy, intended for ...
The FDA has granted fast track designation (FTD) to IVS-3001, an innovative chimeric antigen receptor (CAR) T-cell therapy, intended for ...